1) Financial Performance Overview
- Total revenue for Q1 2026 was $400 million, a $300 million increase YoY, driven by international sales, primarily from the U.K. government partnership.
- Net loss was $1.3 billion on a GAAP basis, or $0.5 billion excluding the litigation settlement.
- Cash and investments at the end of the quarter stood at $7.5 billion, down from $8.1 billion at the end of 2025.
- Cost of sales was $955 million, including $878 million related to the litigation settlement. Excluding this, cost of sales was $77 million, a 14% YoY decline.
- R&D expenses decreased by 24% YoY to $649 million, while SG&A expenses fell by 18% to $173 million.

2) Strategic Developments and Product Pipeline
- Moderna received EU approval for its flu plus COVID combo vaccine (mCOMBRIAX), marking its fourth approved product.
- The company also secured approval for mNEXSPIKE in the EU, positioning it well for the $1.8 billion European respiratory vaccines market.
- A new Phase III trial for Intismeran in non-small cell lung cancer has been initiated, focusing on early-stage disease.
- Upcoming presentations at ASCO and Science Day will provide further insights into pipeline advancements and AI integration in R&D.

3) Market Outlook and Guidance
- Moderna reiterated its guidance for up to 10% revenue growth in 2026, with expectations of revenue between $50 million and $100 million in Q2, split evenly between U.S. and international markets.
- The company anticipates a geographic revenue mix of 50% U.S. and 50% international for the full year.
- Cost of sales projections have increased to $1.8 billion, including the litigation settlement charge.
- R&D expenses are expected to remain around $3 billion, with SG&A expenses projected at $1 billion for 2026.

4) Challenges and Legal Considerations
- The litigation settlement of $950 million is due in Q3 2026, with potential additional payments of up to $1.3 billion depending on the outcome of ongoing legal proceedings.
- Moderna's legal team believes that the likelihood of incurring the additional charge is improbable, thus no charge has been recorded.
- The company does not foresee material impacts from geopolitical conflicts on its 2026 financial outlook.

5) Future Engagements and Investor Relations
- Moderna plans to engage with investors at several upcoming events, including ASCO on June 1 and Science Day on June 25, to discuss pipeline developments and strategic initiatives.
- The transcript lacks detailed information on specific product sales forecasts and market penetration strategies for the newly approved vaccines, which could be critical for understanding future revenue streams.

Bottom line: Moderna's strong Q1 performance, driven by strategic partnerships and new product approvals, positions it well for growth in 2026, despite legal challenges and market uncertainties. The focus on expanding its pipeline and securing market access for new vaccines will be key to achieving its revenue targets.